Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(E)-5-(2-bromovinyl)-2'-deoxyuridine + ATP
(E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate + ADP
1-beta-D-arabinofuranosylcytosine + ATP
1-beta-D-arabinofuranosylcytosine 5'-phosphate + ADP
1-beta-D-arabinofuranosylthymine + ATP
1-beta-D-arabinofuranosylthymine 5'-phosphate + ADP
2',3'-didehydro-3'-deoxythymidine + ATP
2',3'-didehydro-3'-deoxythymidine 5'-phosphate + ADP
-
-
-
-
?
2',3'-dideoxyadenosine + ATP
2',3'-dideoxyadenosine 5'-phosphate + ADP
2',3'-dideoxycytidine + ATP
2',3'-dideoxycytidine 5'-phosphate + ADP
2',3'-dideoxythymidine + ATP
2',3'-dideoxythymidine 5'-phosphate + ADP
4.44% of the activity with thymidine
-
-
?
2'-deoxy-2'-fluoroadenosine 3'-triphosphate + 2'-deoxyadenosine
2'-deoxy-2'-fluoroadenosine 3'-diphosphate + 2'-deoxyadenosine 5'-phosphate
-
low activity
-
-
?
2'-deoxyadenosine + ATP
2'-deoxyadenosine 5'-phosphate + ADP
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
2'-deoxycytidine + CTP
2'-deoxycytidine 5'-phosphate + CDP
-
-
-
-
?
2'-deoxyguanosine + ATP
2'-deoxyguanosine 5'-phosphate + ADP
2'-deoxyuridine + ATP
2'-deoxyuridine 5'-phosphate + ADP
2-chloro-2'-deoxyadenosine + ATP
2-chloro-2'-deoxyadenosine 5'-phosphate + ADP
3'-azido-2',3'-dideoxythymidine + ATP
3'-azido-2',3'-dideoxythymidine 5'-phosphate + ADP
3'-azidothymidine + ATP
3'-azidothymidine 5'-phosphate + ADP
3'-fluoro-2',3'-dideoxythymidine + ATP
3'-fluoro-2',3'-dideoxythymidine 5'-phosphate + ADP
-
0.03% of the activity with thymidine and 2'-deoxycytidine
-
-
?
5-fluoro-2'-deoxyuridine + ATP
5-fluoro-2'-deoxyuridine 5'-phosphate + ADP
adenosine + ATP
adenosine 5'-phosphate + ADP
adenosine-2'-deoxy-2'-fluoro-3'-triphosphate + 2'-deoxycytidine
adenosine-2'-deoxy-2'-fluoro-3'-diphosphate + 2'-deoxycytidine 5'-phosphate
-
low activity
-
-
?
adenosine-2'-deoxy-3'-triphosphate + 2'-deoxyadenosine
adenosine-2'-deoxy-3'-diphosphate + 2'-deoxyadenosine 5'-phosphate
-
low activity
-
-
?
adenosine-2'-deoxy-3'-triphosphate + 2'-deoxycytidine
adenosine-2'-deoxy-3'-diphosphate + 2'-deoxycytidine 5'-phosphate
-
low activity
-
-
?
adenosine-3'-deoxy-2'-triphosphate + 2'-deoxyadenosine
adenosine-3'-deoxy-2'-diphosphate + 2'-deoxyadenosine 5'-phosphate
-
low activity
-
-
?
adenosine-3'-deoxy-2'-triphosphate + 2'-deoxycytidine
adenosine-3'-deoxy-2'-diphosphate + 2'-deoxycytidine 5'-phosphate
-
low activity
-
-
?
adenosine-3'-deoxy-3'-fluoro-2'-triphosphate + 2'-deoxycytidine
adenosine-3'-deoxy-3'-fluoro-2'-diphosphate + 2'-deoxycytidine 5'-phosphate
-
low activity
-
-
?
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
high activity
-
-
?
ATP + 1-(beta-D-arabinofuranosyl)-cytosine
ADP + 1-(beta-D-arabinofuranosyl)-cytosine 5'-phosphate
-
-
-
-
?
ATP + 1-(beta-D-arabinofuranosyl)-thymine
ADP + 1-(beta-D-arabinofuranosyl)-thymine 5'-phosphate
-
-
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
ATP + 1-beta-D-arabinofuranosylguanine
ADP + 1-beta-D-arabinofuranosylguanine 5'-phosphate
-
poor substrate for the wild-type enzyme but moderate activity with N-terminally truncated mutants M88R and V84A/M88R
-
-
?
ATP + 1-beta-D-arabinofuranosylthymine
ADP + 1-beta-D-arabinofuranosylthymine 5'-phosphate
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
ATP + 2',2'-difluorodeoxyguanosine
ADP + 2',2'-difluorodeoxyguanosine 5'-phosphate
-
poor substrate for the wild-type enzyme but moderate activity with N-terminally truncated mutants M88R and V84A/M88R
-
-
?
ATP + 2',3'-didehydro-3'-deoxythymidine
ADP + 2',3'-didehydro-3'-deoxythymidine 5'-phosphate
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
ATP + 2',3'-dideoxythymidine
ADP + 2',3'-dideoxythymidine 5'-phosphate
ATP + 2'-deoxy-2',2'-difluorocytidine
ADP + difluorodeoxycytidine 5'-phosphate
2'-deoxy-2',2'-difluorocytidine is gemcitabine, dNK is an activator of gemcitabine
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
ATP + 2'-deoxyinosine
ADP + 2'-deoxyinosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxynucleoside
ADP + 2'-deoxynucleoside 5'-phosphate
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
ATP + 2-amino-8-(1'-beta-D-2'-deoxyribofuranosyl)-imidazo[1,2-a]-1,3,5-triazin-4(8H)-one
ADP + 2-amino-8-(1'-beta-D-2'-deoxyribofuranosyl)-imidazo[1,2-a]-1,3,5-triazin-4(8H)-one 5'-phosphate
-
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-hydroxy-2'-deoxyadenosine
ADP + 2-hydroxy-2'-deoxyadenosine 5'-monophosphate
preferred substrate for enzyme mutant 4
-
-
?
ATP + 3'-azido-2',3'-didehydro-3'-deoxythymidine
ADP + 3'-azido-2',3'-didehydro-3'-deoxythymidine 5'-phosphate
ATP + 3'-deoxyadenosine
ADP + 3'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 5-(E)-(2-bromvinyl)-2'-deoxyuridine
ADP + 5-(E)-(2-bromvinyl)-2'-deoxyuridine 5'-phosphate
-
-
-
-
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
ATP + 6-amino-5-nitro-3-(1'-beta-D-2'-deoxyribofuranosyl)-2(1H)-pyridone
ADP + 6-amino-5-nitro-3-(1'-beta-D-2'-deoxyribofuranosyl)-2(1H)-pyridone 5'-phosphate
-
-
-
?
ATP + 9-beta-D-arabinofuranosyladenine
ADP + 9-beta-D-arabinofuranosyladenine 5'-phosphate
ATP + a 2'-deoxyribonucleoside
ADP + a 2'-deoxyribonucleoside 5'-phosphate
ATP + aciclovir
ADP + aciclovir phosphate
ATP + adenosine
ADP + adenosine 5'-phosphate
low activity
-
-
?
ATP + arabinosyl-2-fluoroadenine
ADP + arabinosyl-2-fluoroadenine 5'-monophosphate
-
-
-
?
ATP + arabinosyladenine
ADP + arabinosyladenine 5'-monophosphate
-
-
-
?
ATP + arabinosyluridine
ADP + arabinosyluridine 5'-monophosphate
-
-
-
?
ATP + cytidine
ADP + cytidine 5'-phosphate
ATP + deoxyuridine
ADP + deoxyuridine 5'-phosphate
ATP + dideoxycytidine
ADP + dideoxycytidine 5'-phosphate
-
wild-type enzyme: low activity
-
-
?
ATP + E-5-(2-bromovinyl)-2'-deoxyuridine
ADP + E-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
-
-
-
-
?
ATP + E-5-(2-bromovinyl)-2'-deoxyuridine
ADP + E-5-(2-bromovinyl)-2'-deoxyuridine phosphate
ATP + fludarabine
ADP + fludarabine phosphate
-
-
-
?
ATP + ganciclovir
ADP + ganciclovir phosphate
-
poor substrate for the wild-type enzyme but moderate activity with N-terminally truncated mutants M88R and V84A/M88R
-
-
?
ATP + guanosine
ADP + guanosine 5'-phosphate
low activity
-
-
?
ATP + inosine
ADP + inosine 5'-phosphate
very low activity
-
-
?
ATP + stavudine
ADP + stavudine phosphate
ATP + thymidine
ADP + thymidine 5'-phosphate
ATP + uridine
ADP + uridine 5'-phosphate
bromovinyldeoxyuridine + ATP
bromovinyldeoxyuridine 5'-phosphate + ADP
-
specificity constant 930 per s and M
-
-
?
cytidine + ATP
cytidine 5'-phosphate + ADP
difluorodeoxycytidine + ATP
difluorodeoxycytidine 5'-phosphate + ADP
-
i.e. gemcitabine. Efficient in vivo phosphorylation, specificity constant 4800 per s and M
-
-
?
guanosine + ATP
guanosine 5'-phosphate + ADP
thymidine + ATP
thymidine 5'-phosphate + ADP
thymidine + CTP
thymidine 5'-phosphate + CDP
-
-
-
-
?
uridine + ATP
uridine 5'-phosphate + ADP
additional information
?
-
(E)-5-(2-bromovinyl)-2'-deoxyuridine + ATP
(E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate + ADP
-
-
-
-
?
(E)-5-(2-bromovinyl)-2'-deoxyuridine + ATP
(E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate + ADP
-
54% of the activity with thymidine
-
-
?
(E)-5-(2-bromovinyl)-2'-deoxyuridine + ATP
(E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate + ADP
54% of the activity with thymidine
-
-
?
1-beta-D-arabinofuranosylcytosine + ATP
1-beta-D-arabinofuranosylcytosine 5'-phosphate + ADP
-
10% of the activity with thymidine and 2'-deoxycytidine
-
-
?
1-beta-D-arabinofuranosylcytosine + ATP
1-beta-D-arabinofuranosylcytosine 5'-phosphate + ADP
-
58.2% of the activity with thymidine
-
-
?
1-beta-D-arabinofuranosylcytosine + ATP
1-beta-D-arabinofuranosylcytosine 5'-phosphate + ADP
58.2% of the activity with thymidine
-
-
?
1-beta-D-arabinofuranosylcytosine + ATP
1-beta-D-arabinofuranosylcytosine 5'-phosphate + ADP
-
50% of the activity with thymidine and 2'-deoxycytidine
-
-
?
1-beta-D-arabinofuranosylthymine + ATP
1-beta-D-arabinofuranosylthymine 5'-phosphate + ADP
-
15% of the activity with thymidine and 2'-deoxycytidine
-
-
?
1-beta-D-arabinofuranosylthymine + ATP
1-beta-D-arabinofuranosylthymine 5'-phosphate + ADP
-
53.9% of the activity with thymidine
-
-
?
1-beta-D-arabinofuranosylthymine + ATP
1-beta-D-arabinofuranosylthymine 5'-phosphate + ADP
53.9% of the activity with thymidine
-
-
?
2',3'-dideoxyadenosine + ATP
2',3'-dideoxyadenosine 5'-phosphate + ADP
-
0.9% of the activity with thymidine
-
-
?
2',3'-dideoxyadenosine + ATP
2',3'-dideoxyadenosine 5'-phosphate + ADP
0.9% of the activity with thymidine
-
-
?
2',3'-dideoxycytidine + ATP
2',3'-dideoxycytidine 5'-phosphate + ADP
-
-
-
-
?
2',3'-dideoxycytidine + ATP
2',3'-dideoxycytidine 5'-phosphate + ADP
11.1% of the activity with thymidine
-
-
?
2',3'-dideoxycytidine + ATP
2',3'-dideoxycytidine 5'-phosphate + ADP
-
0.02% of the activity with thymidine and 2'-deoxycytidine
-
-
?
2'-deoxyadenosine + ATP
2'-deoxyadenosine 5'-phosphate + ADP
-
specificity constant 33000 per s and M
-
-
?
2'-deoxyadenosine + ATP
2'-deoxyadenosine 5'-phosphate + ADP
-
-
-
-
?
2'-deoxyadenosine + ATP
2'-deoxyadenosine 5'-phosphate + ADP
96% of the activity with thymidine
-
-
?
2'-deoxyadenosine + ATP
2'-deoxyadenosine 5'-phosphate + ADP
-
5% of the activity with thymidine and 2'-deoxycytidine
-
-
?
2'-deoxyadenosine + ATP
2'-deoxyadenosine 5'-phosphate + ADP
-
15% of the activity with thymidine and 2'-deoxycytidine
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
specificity constant 18000 per s and M
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
-
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
-
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
134% of the activity with thymidine
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
-
-
-
?
2'-deoxycytidine + ATP
2'-deoxycytidine 5'-phosphate + ADP
-
-
-
?
2'-deoxyguanosine + ATP
2'-deoxyguanosine 5'-phosphate + ADP
-
specificity constant 10000 per s and M
-
-
?
2'-deoxyguanosine + ATP
2'-deoxyguanosine 5'-phosphate + ADP
-
-
-
-
?
2'-deoxyguanosine + ATP
2'-deoxyguanosine 5'-phosphate + ADP
-
1% of the activity with thymidine and 2'-deoxycytidine
-
-
?
2'-deoxyguanosine + ATP
2'-deoxyguanosine 5'-phosphate + ADP
53% of the activity with thymidine
-
-
?
2'-deoxyguanosine + ATP
2'-deoxyguanosine 5'-phosphate + ADP
-
4% of the activity with thymidine and 2'-deoxycytidine
-
-
?
2'-deoxyuridine + ATP
2'-deoxyuridine 5'-phosphate + ADP
-
specificity constant 410 per s and M
-
-
?
2'-deoxyuridine + ATP
2'-deoxyuridine 5'-phosphate + ADP
-
113% of the activity with thymidine
-
-
?
2'-deoxyuridine + ATP
2'-deoxyuridine 5'-phosphate + ADP
113% of the activity with thymidine
-
-
?
2'-deoxyuridine + ATP
2'-deoxyuridine 5'-phosphate + ADP
-
90% of the activity with thymidine and 2'-deoxycytidine
-
-
?
2-chloro-2'-deoxyadenosine + ATP
2-chloro-2'-deoxyadenosine 5'-phosphate + ADP
-
126% of the activity with thymidine
-
-
?
2-chloro-2'-deoxyadenosine + ATP
2-chloro-2'-deoxyadenosine 5'-phosphate + ADP
126% of the activity with thymidine
-
-
?
3'-azido-2',3'-dideoxythymidine + ATP
3'-azido-2',3'-dideoxythymidine 5'-phosphate + ADP
-
-
-
-
?
3'-azido-2',3'-dideoxythymidine + ATP
3'-azido-2',3'-dideoxythymidine 5'-phosphate + ADP
2% of the activity with thymidine
-
-
?
3'-azidothymidine + ATP
3'-azidothymidine 5'-phosphate + ADP
-
0.5% of the activity with thymidine and 2'-deoxycytidine
-
-
?
3'-azidothymidine + ATP
3'-azidothymidine 5'-phosphate + ADP
-
0.3% of the activity with thymidine and 2'-deoxycytidine
-
-
?
5-fluoro-2'-deoxyuridine + ATP
5-fluoro-2'-deoxyuridine 5'-phosphate + ADP
-
92% of the activity with thymidine
-
-
?
5-fluoro-2'-deoxyuridine + ATP
5-fluoro-2'-deoxyuridine 5'-phosphate + ADP
92% of the activity with thymidine
-
-
?
5-fluoro-2'-deoxyuridine + ATP
5-fluoro-2'-deoxyuridine 5'-phosphate + ADP
-
activity is 10% higher than with thymidine and 2'-deoxycytidine
-
-
?
adenosine + ATP
adenosine 5'-phosphate + ADP
-
0.82% of the activity with thymidine
-
-
?
adenosine + ATP
adenosine 5'-phosphate + ADP
0.82% of the activity with thymidine
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
low activity
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinofuranosylthymine
ADP + 1-beta-D-arabinofuranosylthymine 5'-phosphate
low activity
-
-
?
ATP + 1-beta-D-arabinofuranosylthymine
ADP + 1-beta-D-arabinofuranosylthymine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinofuranosylthymine
ADP + 1-beta-D-arabinofuranosylthymine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinofuranosylthymine
ADP + 1-beta-D-arabinofuranosylthymine 5'-phosphate
-
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
best substrate for the N-terminally truncated mutant M88R
-
-
?
ATP + 2',3'-didehydro-3'-deoxythymidine
ADP + 2',3'-didehydro-3'-deoxythymidine 5'-phosphate
low activity
-
-
?
ATP + 2',3'-didehydro-3'-deoxythymidine
ADP + 2',3'-didehydro-3'-deoxythymidine 5'-phosphate
-
-
-
?
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
-
-
-
?
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
low activity
-
-
?
ATP + 2',3'-dideoxythymidine
ADP + 2',3'-dideoxythymidine 5'-phosphate
-
-
-
?
ATP + 2',3'-dideoxythymidine
ADP + 2',3'-dideoxythymidine 5'-phosphate
low activity
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
48% of the activity with 2'-deoxythymidine
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
2.7% of the activity with 2'-deoxycytidine
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
best substrate for the N-terminally truncated mutant V84A/M88R
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
1% of the activity with 2'-deoxythymidine
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
high activity
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
99% of the activity with 2'-deoxythymidine
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
best substrate
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
wild-type enzyme: second-best substrate
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
88% of the activity with 2'-deoxythymidine
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
high activity
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
83% of the activity with 2'-deoxythymidine
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
0.5% of the activity with 2'-deoxycytidine
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
poor substrate for the wild-type enzyme
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
poor substrate for the wild-type enzyme but moderate activity with N-terminally truncated mutants M88R and V84A/M88R
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
0.2% of the activity with 2'-deoxythymidine
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxynucleoside
ADP + 2'-deoxynucleoside 5'-phosphate
-
-
-
-
ir
ATP + 2'-deoxynucleoside
ADP + 2'-deoxynucleoside 5'-phosphate
-
dNK has a significant preference for pyrimidine deoxynucleosides over purine deoxynucleosides, but it does phosphorylate deoxyadenosine and deoxyguanosine at significant rates
-
-
?
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
-
-
-
?
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
-
-
-
?
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
-
-
-
?
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
-
-
-
?
ATP + 2'-deoxyribonucleoside
ADP + 2'-deoxyribonucleoside 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
best substrate
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
high activity
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
65% of the activity with 2'-deoxycytidine
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
best substrate
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
2'-deoxythymidine binding structure at the active site, overview
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
best substrate for the wild-type enzyme
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
substrate binding structure of mutant N64D
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
best substrate
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
best substrate
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
high activity
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
low activity
-
-
?
ATP + 3'-azido-2',3'-didehydro-3'-deoxythymidine
ADP + 3'-azido-2',3'-didehydro-3'-deoxythymidine 5'-phosphate
low activity
-
-
?
ATP + 3'-azido-2',3'-didehydro-3'-deoxythymidine
ADP + 3'-azido-2',3'-didehydro-3'-deoxythymidine 5'-phosphate
-
-
-
-
?
ATP + 3'-azido-2',3'-didehydro-3'-deoxythymidine
ADP + 3'-azido-2',3'-didehydro-3'-deoxythymidine 5'-phosphate
low activity
-
-
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
-
-
-
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
high activity
-
-
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
-
-
-
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
high activity
-
-
?
ATP + 9-beta-D-arabinofuranosyladenine
ADP + 9-beta-D-arabinofuranosyladenine 5'-phosphate
-
-
-
?
ATP + 9-beta-D-arabinofuranosyladenine
ADP + 9-beta-D-arabinofuranosyladenine 5'-phosphate
-
poor substrate for the wild-type enzyme but moderate activity with N-terminally truncated mutants M88R and V84A/M88R
-
-
?
ATP + 9-beta-D-arabinofuranosyladenine
ADP + 9-beta-D-arabinofuranosyladenine 5'-phosphate
very low activity
-
-
?
ATP + a 2'-deoxyribonucleoside
ADP + a 2'-deoxyribonucleoside 5'-phosphate
-
-
-
-
?
ATP + a 2'-deoxyribonucleoside
ADP + a 2'-deoxyribonucleoside 5'-phosphate
-
-
-
?
ATP + a 2'-deoxyribonucleoside
ADP + a 2'-deoxyribonucleoside 5'-phosphate
-
-
-
-
?
ATP + aciclovir
ADP + aciclovir phosphate
-
-
-
?
ATP + aciclovir
ADP + aciclovir phosphate
-
-
-
-
?
ATP + cytidine
ADP + cytidine 5'-phosphate
-
-
-
?
ATP + cytidine
ADP + cytidine 5'-phosphate
-
-
-
?
ATP + cytidine
ADP + cytidine 5'-phosphate
very low activity
-
-
?
ATP + deoxyuridine
ADP + deoxyuridine 5'-phosphate
best substrate
-
-
?
ATP + deoxyuridine
ADP + deoxyuridine 5'-phosphate
high activity
-
-
?
ATP + E-5-(2-bromovinyl)-2'-deoxyuridine
ADP + E-5-(2-bromovinyl)-2'-deoxyuridine phosphate
-
-
-
-
?
ATP + E-5-(2-bromovinyl)-2'-deoxyuridine
ADP + E-5-(2-bromovinyl)-2'-deoxyuridine phosphate
-
-
-
?
ATP + stavudine
ADP + stavudine phosphate
anti-HIV nucleoside analogue
-
-
?
ATP + stavudine
ADP + stavudine phosphate
anti-HIV nucleoside analogue
-
-
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
-
-
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
wild-type enzyme: preferred substrate
-
-
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
-
-
-
?
ATP + uridine
ADP + uridine 5'-phosphate
low activity
-
-
?
ATP + uridine
ADP + uridine 5'-phosphate
very low activity
-
-
?
ATP + uridine
ADP + uridine 5'-phosphate
very low activity
-
-
?
cytidine + ATP
cytidine 5'-phosphate + ADP
-
16% of the activity with thymidine
-
-
?
cytidine + ATP
cytidine 5'-phosphate + ADP
16% of the activity with thymidine
-
-
?
guanosine + ATP
guanosine 5'-phosphate + ADP
-
1.18% of the activity with thymidine
-
-
?
guanosine + ATP
guanosine 5'-phosphate + ADP
1.18% of the activity with thymidine
-
-
?
thymidine + ATP
thymidine 5'-phosphate + ADP
-
-
-
-
?
thymidine + ATP
thymidine 5'-phosphate + ADP
-
-
-
?
thymidine + ATP
thymidine 5'-phosphate + ADP
-
-
-
-
?
thymidine + ATP
thymidine 5'-phosphate + ADP
-
-
-
-
?
uridine + ATP
uridine 5'-phosphate + ADP
-
6.45% of the activity with thymidine
-
-
?
uridine + ATP
uridine 5'-phosphate + ADP
6.45% of the activity with thymidine
-
-
?
additional information
?
-
substrate specificity, no activity with cytidine, adenine, guanine, and thymine, no activity with dideoxynucleosides, and with 3'-azido-2',3'-didehydro-3'-deoxythymidine
-
-
?
additional information
?
-
-
substrate specificity, no activity with cytidine, adenine, guanine, and thymine, no activity with dideoxynucleosides, and with 3'-azido-2',3'-didehydro-3'-deoxythymidine
-
-
?
additional information
?
-
the multisubstrate kinase from from Anopheles gambiae (AgdNK) prefers purines
-
-
?
additional information
?
-
substrate binding of non-TK1-like dNKs, overview
-
-
?
additional information
?
-
-
no substrate: deoxythymidine
-
-
?
additional information
?
-
substrate specificity, no activity with 2-deoxyribose, dideoxyadenosine, dideoxyguanosine, adenosine, and guanosine
-
-
?
additional information
?
-
-
substrate specificity, no activity with 2-deoxyribose, dideoxyadenosine, dideoxyguanosine, adenosine, and guanosine
-
-
?
additional information
?
-
-
substrate specificity, no activity with purine ribonucleosides and dideoxynucleosides
-
-
?
additional information
?
-
the multisubstrate kinase from Bombyx mori (BmdNK) prefers pyrimidines
-
-
?
additional information
?
-
substrate binding of non-TK1-like dNKs, overview
-
-
?
additional information
?
-
-
substrate specificity
-
-
?
additional information
?
-
-
broad substrate specificity
-
-
?
additional information
?
-
broad substrate specificity
-
-
?
additional information
?
-
-
no activity with acyclovir
-
-
?
additional information
?
-
-
no activity with acyclovir
-
-
?
additional information
?
-
-
activity with CTP is 110% of the activity ATP
-
-
?
additional information
?
-
the recombinant enzyme preferentially phosphorylates the pyrimidine nucleosides, but phosphorylation of the purine nucleosidesis also efficiently catalyzed
-
-
?
additional information
?
-
-
the recombinant enzyme preferentially phosphorylates the pyrimidine nucleosides, but phosphorylation of the purine nucleosidesis also efficiently catalyzed
-
-
?
additional information
?
-
-
no activity with dTMP
-
-
?
additional information
?
-
-
no activity with TMP
-
-
?
additional information
?
-
no activity with TMP
-
-
?
additional information
?
-
-
no activity with TMP
-
-
?
additional information
?
-
-
CTP has the same phosphotransfer capability as ATP
-
-
?
additional information
?
-
-
enzyme evolution by gene duplication of a progenitor kinase
-
-
?
additional information
?
-
enzyme shows broad substrate specificity, this enzyme specificity-type is the earliest in evolution probably encoded by the so-called dCK/dGK/TK2-like gene, several duplications of the progenitor gene are the reason for evolutionary occurring of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, insects lost all but 1 nucleotide kinase, overview
-
-
?
additional information
?
-
-
amino acid residues responsible for substrate specificity are V84, M88, and A110, wild-type enzyme shows broad substrate specificity preferring pyrimidines to purines, substrate specificities of wild-type and mutant enzymes, overview
-
-
?
additional information
?
-
enzyme shows broad substrate specificity involving V84, M88, and A110
-
-
?
additional information
?
-
-
no activity with adenosine-3'-deoxy-3'-fluoroxylo-2'-triphosphate and adenosine-2'-deoxy-3'-fluoroara-3'-triphosphate as phosphate donors
-
-
?
additional information
?
-
-
no activity with diphosphate, or triphosphate as phosphate donors
-
-
?
additional information
?
-
-
substrate specificities of wild-type and mutant enzymes, overview, no or poor activity with ganciclovir
-
-
?
additional information
?
-
the enzyme shows broad substrate specificity probably due to a wide substrate binding cleft
-
-
?
additional information
?
-
-
dNK plays a role in cell proliferation in physiological conditions
-
-
?
additional information
?
-
-
transient expression of Drosophila melanogaster deoxynucleoside kinase gene in HeLa cells enhances cytotoxicity of nucleoside analogs
-
-
?
additional information
?
-
the multisubstrate kinase from Drosophila prefers pyrimidines
-
-
?
additional information
?
-
Dm-dNK phosphorylates a broad range of substrates including analogues of both purine and pyrimidine nucleosides, and exhibits a higher activity than other nucleoside kinases
-
-
?
additional information
?
-
-
Dm-dNK phosphorylates a broad range of substrates including analogues of both purine and pyrimidine nucleosides, and exhibits a higher activity than other nucleoside kinases
-
-
?
additional information
?
-
enzyme DmdNK is able to phosphorylate all four natural 2'-deoxyribonucleosides with high efficiency, it shows broad specificity and high turnover towards the naturally occurring 2'-deoxyribonucleosides and a similar broad specificity towards nucleoside analogues used in chemotherapy, substrate specificity towards natural and non-natural nucleosides, overview
-
-
?
additional information
?
-
substrate binding of non-TK1-like dNKs, overview
-
-
?
additional information
?
-
-
no activity with acyclovir
-
-
?
additional information
?
-
-
no activity with TMP
-
-
?
additional information
?
-
-
CTP has the same phosphotransfer capability as ATP
-
-
?
additional information
?
-
-
no activity with acyclovir
-
-
?
additional information
?
-
-
activity with CTP is 110% of the activity ATP
-
-
?
additional information
?
-
-
no activity with dTMP
-
-
?
additional information
?
-
substrate specificity, no activity with fludarabine, 3'-deoxyadenosine, 2',3'-didehydro-3'-deoxythymidine, 2-deoxyribose, dideoxyadenosine, dideoxyguanosine, adenosine, and guanosine
-
-
?
additional information
?
-
-
substrate specificity, no activity with fludarabine, 3'-deoxyadenosine, 2',3'-didehydro-3'-deoxythymidine, 2-deoxyribose, dideoxyadenosine, dideoxyguanosine, adenosine, and guanosine
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Breast Neoplasms
Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy.
Breast Neoplasms
Cytotoxic effects of adenovirus- and lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase on Bcap37 breast cancer cells.
Breast Neoplasms
Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: a potential strategy for cancer therapy.
Breast Neoplasms
Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
Breast Neoplasms
Potent anticancer effects of lentivirus encoding a Drosophila melanogaster deoxyribonucleoside kinase mutant combined with brivudine.
Breast Neoplasms
Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Breast Neoplasms
Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo.
Breast Neoplasms
The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells.
Colorectal Neoplasms
Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Colorectal Neoplasms
Potent anticancer effects of lentivirus encoding a Drosophila melanogaster deoxyribonucleoside kinase mutant combined with brivudine.
deoxycytidine kinase deficiency
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Herpes Simplex
5'-Amino-5'-deoxythymidine: synthesis, specific phosphorylation by herpesvirus thymidine kinase, and stability to pH of the enzymically formed diphosphate derivative.
Herpes Simplex
Abnormal properties of an immediate early polypeptide in cells infected with the herpes simplex virus type 1 mutant tsK.
Herpes Simplex
Active site mutants of Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Herpes Simplex
Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile.
Herpes Simplex
Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus.
Herpes Simplex
Cell-free synthesis of herpes simplex virus-coded pyrimidine deoxyribonucleoside kinase enzyme.
Herpes Simplex
Characterization of pyrimidine deoxyribonucleoside kinase (thymidine kinase) and thymidylate kinase as a multifunctional enzyme in cells transformed by herpes simplex virus type 1 and in cells infected with mutant strains of herpes simplex virus.
Herpes Simplex
Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster.
Herpes Simplex
Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy.
Herpes Simplex
Design, synthesis and enzymatic activity of highly selective human mitochondrial thymidine kinase inhibitors.
Herpes Simplex
Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines.
Herpes Simplex
Herpesvirus proteins: DNA polymerase and pyrimidine deoxynucleoside kinase activities in temperature-sensitive mutants of herpes simplex virus type 2.
Herpes Simplex
Lipid-mediated protein delivery of suicide nucleoside kinases.
Herpes Simplex
N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors.
Herpes Simplex
Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK and Drosophila melanogaster multifunctional deoxynucleoside kinase.
Herpes Simplex
Physical mapping of herpes simplex virus type 1 mutations by marker rescue.
Herpes Simplex
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
Herpes Simplex
[Cloning, expression, isolation and properties of thymidine kinase herpes simplex virus, strain L2].
Infections
Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Keloid
Efficacy of lentivirus?mediated Drosophila melanogaster deoxyribonucleoside kinase combined with (E)?5?(2?bromovinyl)?2'?deoxyuridine or 1???D?arabinofuranosylthymine therapy in human keloid fibroblasts.
Leukemia L1210
Deoxyguanosine-resistant leukemia L1210 cells. Loss of specific deoxyribonucleoside kinase activity.
Leukemia L1210
Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Malaria
Mosquito has a single multisubstrate deoxyribonucleoside kinase characterized by unique substrate specificity.
Neoplasms
Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile.
Neoplasms
Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Neoplasms
Bystander effects of cancer cell lines transduced with the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster and synergistic enhancement by hydroxyurea.
Neoplasms
Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster.
Neoplasms
Cytotoxic effect of Drosophila deoxynucleoside kinase gene on replicating plasmid in HeLa cells.
Neoplasms
Cytotoxic effects of adenovirus- and lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase on Bcap37 breast cancer cells.
Neoplasms
Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine.
Neoplasms
Efficacy of lentivirus?mediated Drosophila melanogaster deoxyribonucleoside kinase combined with (E)?5?(2?bromovinyl)?2'?deoxyuridine or 1???D?arabinofuranosylthymine therapy in human keloid fibroblasts.
Neoplasms
Enhanced toxicity of purine nucleoside analogs in cells expressing Drosophila melanogaster nucleoside kinase mutants.
Neoplasms
Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: a potential strategy for cancer therapy.
Neoplasms
Mitochondrial expression of the Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Neoplasms
Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
Neoplasms
Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol.
Neoplasms
Potent anticancer effects of lentivirus encoding a Drosophila melanogaster deoxyribonucleoside kinase mutant combined with brivudine.
Neoplasms
Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells.
Neoplasms
Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Neoplasms
Synergistic therapeutic effect in gastric cancer cells produced by oncolytic adenovirus encoding Drosophila melanogaster deoxyribonucleoside kinase.
Neoplasms
Tanshinone IIA enhances bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in nuclei and mitochondria.
Neoplasms
The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells.
Osteosarcoma
Tanshinone IIA enhances bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in nuclei and mitochondria.
Sarcoma
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Stomach Neoplasms
Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: a potential strategy for cancer therapy.
Stomach Neoplasms
Potent anticancer effects of lentivirus encoding a Drosophila melanogaster deoxyribonucleoside kinase mutant combined with brivudine.
Stomach Neoplasms
Retrovirus-mediated Drosophila melanogaster multisubstrate deoxyribonucleoside kinase gene therapy of gastric cancer cells in vitro and in vivo.
Stomach Neoplasms
Synergistic therapeutic effect in gastric cancer cells produced by oncolytic adenovirus encoding Drosophila melanogaster deoxyribonucleoside kinase.
Superinfection
Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines.
Triple Negative Breast Neoplasms
Gemcitabine resistance in triple-negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0045
(E)-5-(2-bromovinyl)-2'-deoxyuridine
-
37°C, fusion protein with glutathione S-transferase
0.0243 - 1.441
1-(beta-D-arabinofuranosyl)-cytosine
0.062 - 0.357
1-(beta-D-arabinofuranosyl)-thymine
0.028
1-beta-D-arabinofuranosylcytosine
-
-
1.093 - 1.124
2',3'-dideoxycytidine
0.0207
2'-deoxy-2',2'-difluorocytidine
-
0.0181 - 3.82
2'-deoxyadenosine
0.0009 - 2.162
2'-deoxycytidine
0.0095 - 20.35
2'-deoxyguanosine
0.0009 - 5.02
2'-deoxythymidine
0.0217 - 0.09
2-amino-8-(1'-beta-D-2'-deoxyribofuranosyl)-imidazo[1,2-a]-1,3,5-triazin-4(8H)-one
-
0.0111 - 0.0117
3'-azido-2',3'-didehydro-3'-deoxythymidine
0.0072 - 0.0083
3'-azido-2',3'-dideoxythymidine
0.0022 - 0.0049
5-(E)-(2-bromvinyl)-2'-deoxyuridine
0.00068 - 0.1017
6-amino-5-nitro-3-(1'-beta-D-2'-deoxyribofuranosyl)-2(1H)-pyridone
-
0.292 - 1.124
Dideoxycytidine
additional information
additional information
-
0.0243
1-(beta-D-arabinofuranosyl)-cytosine
-
37°C, pH 7.5, wild-type enzyme
1.441
1-(beta-D-arabinofuranosyl)-cytosine
-
37°C, pH 7.5, mutant enzyme Y70W
0.062
1-(beta-D-arabinofuranosyl)-thymine
-
37°C, pH 7.5, wild-type enzyme
0.357
1-(beta-D-arabinofuranosyl)-thymine
-
37°C, pH 7.5, mutant enzyme Y70W
1.093
2',3'-dideoxycytidine
-
mutant enzyme N45D/N64D
1.124
2',3'-dideoxycytidine
-
-
0.0181
2'-deoxyadenosine
pH 8.0, recombinant enzyme
0.109
2'-deoxyadenosine
-
pH 8.0, 22°C
0.119
2'-deoxyadenosine
-
recombinant mutant N45D
0.15
2'-deoxyadenosine
-
recombinant mutant V84S
0.153
2'-deoxyadenosine
-
recombinant mutant V84A/M88R/A110D
0.225
2'-deoxyadenosine
-
recombinant wild-type enzyme
0.225
2'-deoxyadenosine
pH 7.8, 22°C, recombinant enzyme
0.239
2'-deoxyadenosine
-
recombinant mutant A110D
0.36
2'-deoxyadenosine
-
recombinant mutant M88R/A110D
0.373
2'-deoxyadenosine
pH 8, 37°C
0.373
2'-deoxyadenosine
-
pH 7.6, 37°C, recombinant wild-type enzyme
0.388
2'-deoxyadenosine
-
recombinant mutant V84S/M88R/A110D
0.501
2'-deoxyadenosine
-
0.625
2'-deoxyadenosine
-
pH 7.6, 37°C, recombinant mutant Q81N
0.7
2'-deoxyadenosine
-
recombinant mutant V84A
0.852
2'-deoxyadenosine
-
recombinant mutant V84M
2.088
2'-deoxyadenosine
-
recombinant mutant M88R
3.16
2'-deoxyadenosine
-
mutant enzyme N45D/N64D
3.82
2'-deoxyadenosine
-
recombinant mutant N64D
0.0009
2'-deoxycytidine
-
recombinant mutant N45D
0.001
2'-deoxycytidine
-
pH 8.0, 22°C
0.0023
2'-deoxycytidine
-
recombinant wild-type enzyme
0.0023
2'-deoxycytidine
pH 7.8, 22°C, recombinant enzyme
0.0023
2'-deoxycytidine
-
37°C, pH 7.5, wild-type enzyme
0.0025
2'-deoxycytidine
-
recombinant mutant V84A
0.0026
2'-deoxycytidine
pH 8, 37°C
0.0037
2'-deoxycytidine
-
37°C, pH 7.5, mutant enzyme E52D
0.0058
2'-deoxycytidine
-
37°C, pH 7.5, mutant enzyme E52H
0.0061
2'-deoxycytidine
-
0.0087
2'-deoxycytidine
wild type enzyme, at pH 7.6 and 37°C
0.0113
2'-deoxycytidine
mutant enzyme Q81E, at pH 7.6 and 37°C
0.0126
2'-deoxycytidine
pH 8.0, recombinant enzyme
0.0129
2'-deoxycytidine
-
recombinant mutant V84S
0.091
2'-deoxycytidine
-
recombinant mutant A110D
0.0964
2'-deoxycytidine
-
mutant enzyme N45D/N64D
0.113
2'-deoxycytidine
-
37°C, pH 7.5, mutant enzyme R105H
0.118
2'-deoxycytidine
-
recombinant mutant N64D
0.205
2'-deoxycytidine
-
37°C, pH 7.5, mutant enzyme Q81N
0.246
2'-deoxycytidine
-
37°C, pH 7.5, mutant enzyme Y70W
0.584
2'-deoxycytidine
-
recombinant mutant M88R/A110D
0.627
2'-deoxycytidine
-
recombinant mutant V84A/M88R/A110D
0.674
2'-deoxycytidine
-
recombinant mutant V84M
1.039
2'-deoxycytidine
-
recombinant mutant M88R
2.162
2'-deoxycytidine
-
recombinant mutant V84S/M88R/A110D
0.0095
2'-deoxyguanosine
pH 8.0, recombinant enzyme
0.04
2'-deoxyguanosine
-
recombinant mutant V84A/M88R/A110D
0.147
2'-deoxyguanosine
-
recombinant mutant V84A
0.159
2'-deoxyguanosine
-
recombinant mutant V84S/M88R/A110D
0.257
2'-deoxyguanosine
-
recombinant mutant A110D
0.375
2'-deoxyguanosine
-
recombinant mutant V84S
0.412
2'-deoxyguanosine
-
recombinant mutant N45D
0.429
2'-deoxyguanosine
-
0.4307
2'-deoxyguanosine
wild type enzyme, at pH 7.6 and 37°C
0.549
2'-deoxyguanosine
-
recombinant mutant M88R/A110D
0.645
2'-deoxyguanosine
-
recombinant mutant M88R
0.654
2'-deoxyguanosine
-
pH 8.0, 22°C
0.665
2'-deoxyguanosine
-
recombinant wild-type enzyme
0.665
2'-deoxyguanosine
pH 7.8, 22°C, recombinant enzyme
0.985
2'-deoxyguanosine
-
pH 7.6, 37°C, recombinant mutant Q81N
1.612
2'-deoxyguanosine
mutant enzyme Q81E, at pH 7.6 and 37°C
1.911
2'-deoxyguanosine
-
recombinant mutant V84M
2
2'-deoxyguanosine
pH 8, 37°C
2
2'-deoxyguanosine
-
pH 7.6, 37°C, recombinant wild-type enzyme
2.004
2'-deoxyguanosine
-
mutant enzyme N45D/N64D
20.35
2'-deoxyguanosine
-
recombinant mutant N64D
0.0009
2'-deoxythymidine
-
recombinant mutants N45D
0.0012
2'-deoxythymidine
-
37°C, pH 7.5, wild-type enzyme
0.0025
2'-deoxythymidine
-
pH 7.6, 37°C, recombinant wild-type enzyme
0.0025
2'-deoxythymidine
-
recombinant wild-type enzyme, pH 7.6, 37°C
0.0031
2'-deoxythymidine
-
pH 7.6, 37°C, recombinant mutant F114A
0.0037
2'-deoxythymidine
-
37°C, pH 7.5, mutant enzyme E52H
0.0038
2'-deoxythymidine
-
37°C, pH 7.5, mutant enzyme E52D
0.0047
2'-deoxythymidine
-
pH 7.6, 37°C, recombinant mutant Q81N
0.0058
2'-deoxythymidine
pH 8.0, recombinant enzyme
0.0089
2'-deoxythymidine
-
37°C, pH 7.5, mutant enzyme R105H
0.0153
2'-deoxythymidine
-
0.022
2'-deoxythymidine
-
pH 7.6, 37°C, recombinant mutant F114Y
0.0232
2'-deoxythymidine
-
recombinant mutant N64D
0.1
2'-deoxythymidine
-
above, pH 7.6, 37°C, recombinant mutants I29H and Q81D
0.138
2'-deoxythymidine
-
0.231
2'-deoxythymidine
-
37°C, pH 7.5, mutant enzyme Q81N
0.251
2'-deoxythymidine
-
37°C, pH 7.5, mutant enzyme Y70W
0.79
2'-deoxythymidine
-
recombinant N-terminally truncated mutant M88R, pH 7.6, 37°C
0.93
2'-deoxythymidine
-
recombinant mutant M88R, pH 7.6, 37°C
3.3
2'-deoxythymidine
-
recombinant N-terminally truncated mutant V84A/M88R, pH 7.6, 37°C
5.02
2'-deoxythymidine
-
recombinant mutant V84A/M88R, pH 7.6, 37°C
0.0217
2-amino-8-(1'-beta-D-2'-deoxyribofuranosyl)-imidazo[1,2-a]-1,3,5-triazin-4(8H)-one
mutant enzyme Q81E, at pH 7.6 and 37°C
-
0.09
2-amino-8-(1'-beta-D-2'-deoxyribofuranosyl)-imidazo[1,2-a]-1,3,5-triazin-4(8H)-one
wild type enzyme, at pH 7.6 and 37°C
-
0.0111
3'-azido-2',3'-didehydro-3'-deoxythymidine
-
recombinant mutant N64D
0.0117
3'-azido-2',3'-didehydro-3'-deoxythymidine
-
recombinant mutant N45D
0.0072
3'-azido-2',3'-dideoxythymidine
-
mutant enzyme N45D/N64D
0.0083
3'-azido-2',3'-dideoxythymidine
-
-
0.0022
5-(E)-(2-bromvinyl)-2'-deoxyuridine
-
37°C, pH 7.5, wild-type enzyme
0.0049
5-(E)-(2-bromvinyl)-2'-deoxyuridine
-
37°C, pH 7.5, mutant enzyme Y70W
0.00068
6-amino-5-nitro-3-(1'-beta-D-2'-deoxyribofuranosyl)-2(1H)-pyridone
mutant enzyme Q81E, at pH 7.6 and 37°C
-
0.1017
6-amino-5-nitro-3-(1'-beta-D-2'-deoxyribofuranosyl)-2(1H)-pyridone
wild type enzyme, at pH 7.6 and 37°C
-
0.0014
ATP
-
-
0.0014
ATP
-
pH 8.0, 22°C, reaction with 2'-deoxycytidine
0.0022
ATP
-
pH 8.0, 22°C, reaction with thymidine
0.292
Dideoxycytidine
-
recombinant mutant V84A
1.124
Dideoxycytidine
-
recombinant wild-type enzyme
0.92
ganciclovir
-
recombinant mutant M88R, pH 7.6, 37°C
1.2
ganciclovir
-
recombinant N-terminally truncated mutant M88R, pH 7.6, 37°C
1.75
ganciclovir
-
recombinant N-terminally truncated mutant V84A/M88R, pH 7.6, 37°C
2.68
ganciclovir
-
recombinant mutant V84A/M88R, pH 7.6, 37°C
5.06
ganciclovir
-
recombinant mutant V84A/M88R/A110D, pH 7.6, 37°C
0.0009
thymidine
-
pH 8.0, 22°C
0.001
thymidine
-
pH 8.0, 22°C
0.0012
thymidine
-
recombinant wild-type enzyme
0.0012
thymidine
pH 7.8, 22°C, recombinant enzyme
0.0016
thymidine
pH 8, 37°C
0.0113
thymidine
-
recombinant mutant V84A
0.0242
thymidine
-
mutant enzyme N45D/N64D
0.0247
thymidine
-
recombinant mutant V84S
0.064
thymidine
-
recombinant mutant A110D
0.237
thymidine
-
recombinant mutant M88R
0.829
thymidine
-
recombinant mutant V84M
1.512
thymidine
-
recombinant mutant V84A/M88R/A110D
2.425
thymidine
-
recombinant mutant M88R/A110D
6.56
thymidine
-
recombinant mutant V84S/M88R/A110D
additional information
additional information
kinetics
-
additional information
additional information
-
kinetics
-
additional information
additional information
kinetics
-
additional information
additional information
-
kinetics
-
additional information
additional information
-
Km-values of chimeric enzymes
-
additional information
additional information
-
positive cooperativity with all 4 natural deoxyribonucleosides, no hyperbolic Michaelis-Menten substrate kinetics
-
additional information
additional information
straight forward hyperbolic kinetic reaction mechanism following a compulsory ordered steady-state reaction mechanism with formation of a ternary complex
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
A110D
-
site-directed mutagenesis, altered substrate specificity and kinetics, and highly reduced activity compared to the wild-type enzyme
E52D
-
markedly decreased kcat
E52H
-
markedly decreased kcat
E52Q
-
inactive mutant protein
F114A
-
site-directed mutagenesis, active site mutant, altered substrate specificity compared to the wild-type enzyme
F114Y
-
site-directed mutagenesis, active site mutant, altered substrate specificity compared to the wild-type enzyme
I102M/N117S/M118V/D208N
-
clones harbouring the mutant enzyme are more sensitive to 3'-azido-2',3'-dideoxythymidine and beta-D-arabinofuranosylcytosine
I29H
-
site-directed mutagenesis, active site mutant, altered substrate specificity compared to the wild-type enzyme
I29H/F114Y
-
site-directed mutagenesis, active site mutant, inactive mutant
I47T/N210D
-
clones harbouring the mutant enzyme are more sensitive to 3'-azido-2',3'-dideoxythymidine and beta-D-arabinofuranosylcytosine
M1T/T85A/N121S
-
clones harbouring the mutant enzyme are more sensitive to 1-beta-D-arabinofuranosylcytosine and 2',3'-dideoxycytidine
M88R/A110D
-
site-directed mutagenesis, altered substrate specificity and kinetics, and highly reduced activity compared to the wild-type enzyme
N210D/L239P
-
clones harbouring the mutant enzyme are more sensitive to 3'-azido-2',3'-dideoxythymidine and beta-D-arabinofuranosylcytosine
N28P
-
site-directed mutagenesis, active site mutant, inactive mutant
N28P/I29H
-
site-directed mutagenesis, active site mutant, inactive mutant
N28P/I29H/F114Y
-
site-directed mutagenesis, active site mutant, inactive mutant
N38D/N64D
-
clones harbouring the mutant enzyme are more sensitive specifically to 3'-azido-2',3'-dideoxythymidine
N45D
-
site-directed mutagenesis, decreased activity with natural substrates
N59D/M118V/Y179H
-
clones harbouring the mutant enzyme are more sensitive to 3'-azido-2',3'-dideoxythymidine and beta-D-arabinofuranosylcytosine
N64D
-
site-directed mutagenesis, highly decreased activity with natural substrates, decreased feedback inhibition by dTTP compared to the wild-type enzyme
N64S/L68S/M69L
-
clones harbouring the mutant enzyme are more sensitive specifically to 3'-azido-2',3'-dideoxythymidine
Q81D
-
site-directed mutagenesis, active site mutant, inactive mutant
Q81E
the mutant enzyme shows higher phosphorylating activity with 6-amino-5-nitro-3-(1'-beta-D-2'-deoxyribofuranosyl)-2(1H)-pyridone as compared to the wild type enzyme
R105H
-
markedly decreased kcat
R105K
-
inactive mutant protein
R247S
-
site-directed mutagenesis, mutation abolishes nuclear import of the enzyme, the mutant enzyme is localized in the cytosol
T12A/V84A/N213S
-
clones harbouring the mutant enzyme are more sensitive to 1-beta-D-arabinofuranosylcytosine
T85A
-
clones harbouring the mutant enzyme are more sensitive to 1-beta-D-arabinofuranosylcytosine and 2',3'-dideoxycytidine
V84A/M88R
-
site-directed mutagenesis of the full length enzyme and of the DELTA20 N-terminally truncated enzyme, highly increased Km for acceptor substrates, altered substrate specificity compared to the wild-type enzyme
V84M
-
site-directed mutagenesis, altered substrate specificity and kinetics, and highly reduced activity compared to the wild-type enzyme
V84S
-
site-directed mutagenesis, altered substrate specificity and kinetics, and reduced activity compared to the wild-type enzyme
V84S/M88R/A110D
-
site-directed mutagenesis, altered substrate specificity and kinetics, and highly reduced activity compared to the wild-type enzyme
Y70W
-
mutant enzyme loses activity towards purines. Negative cooperativity towards dThd and dCyd is observed
L349V
-
the mutation significantly reduces the enzyme activity
M88R
-
site-directed mutagenesis of the full length enzyme and of the DELTA20 N-terminally truncated enzyme, highly increased Km for acceptor substrates, altered substrate specificity compared to the wild-type enzyme
M88R
-
site-directed mutagenesis, altered substrate specificity and kinetics, and highly reduced activity compared to the wild-type enzyme
N45D/N64D
-
clones harbouring the mutant enzyme are more sensitive to 3'-azido-2',3'-dideoxythymidine and other nucleoside analogs
N45D/N64D
-
mutant enzyme with the largest und universal increase in sensitivity of all mutants tested. 316fold increase to 3'-azido-2',3'-dideoxythymidine, more than 11fold to 2',3'-dideoxycytidine, and 3.2fold increase in sensitivity to beta-D-arabinofuranosylcytosine and 2',3'-dideoxyadenosine. Higher Km-values for native substrates than wild-type enzyme and Vmax-values are substantially lower, decrease in feedback inhibition by TTP, Km and Vmax values for 3'-azido-2',3'-dideoxythymidine and Km value for 2',3'-dideoxycytidine are nearly unchanged
N45D/N64D
-
decreased activity with natural substrates, decreased feedback inhibition by dTTP compared to the wild-type enzyme
N45D/N64D
site-directed mutagenesis, mutant shows increased drug sensitivity and decreased inhibition by dTTP compared to the wild-type enzyme
N45D/N64D
-
enhanced cytotoxicity for parimidine analogs especially azidothymidine
Q81N
-
site-directed mutagenesis, active site mutant, altered substrate specificity compared to the wild-type enzyme
Q81N
-
mutation shows a 200fold and 100fold increase in Km. kcat is decreased 5fold and 2fold for dThd and dCyd
V84A
-
clones harbouring the mutant enzyme are more sensitive to 1-beta-D-arabinofuranosylcytosine
V84A
-
site-directed mutagenesis, altered substrate specificity and kinetics, and reduced activity compared to the wild-type enzyme
V84A/M88R/A110D
-
site-directed mutagenesis of the full length enzyme and of the DELTA20 N-terminally truncated enzyme, highly increased Km for acceptor substrates, altered substrate specificity compared to the wild-type enzyme
V84A/M88R/A110D
-
site-directed mutagenesis, altered substrate specificity and kinetics, and highly reduced activity compared to the wild-type enzyme
additional information
the deletion mutants rDm-dNKDELTAC10 and rDm-dNKDELTAC20 show the same substrate activity pattern as the recombinant wild-type enzyme. Relative phosphorylation of 2'-deoxycytidine and 2-chloro-2'-deoxyadenosine increases with increasing C-terminal truncation. The relative activities of rDm-dNKDELTAC10 and rDm-dNKDELTAC20 with deoxyribonucleosides remains largely unchanged, whereas there is a substantial decrease in the phosphorylation of the purine ribonucleosides adenosine and guanosine, as well as of all dideoxyribonucleosides and 3'-azido-2',3'-dideoxythymidine. The relative activities with the pyrimidine ribonucleosides and 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylthymine are not affected by the C-terminal deletions
additional information
-
the deletion mutants rDm-dNKDELTAC10 and rDm-dNKDELTAC20 show the same substrate activity pattern as the recombinant wild-type enzyme. Relative phosphorylation of 2'-deoxycytidine and 2-chloro-2'-deoxyadenosine increases with increasing C-terminal truncation. The relative activities of rDm-dNKDELTAC10 and rDm-dNKDELTAC20 with deoxyribonucleosides remains largely unchanged, whereas there is a substantial decrease in the phosphorylation of the purine ribonucleosides adenosine and guanosine, as well as of all dideoxyribonucleosides and 3'-azido-2',3'-dideoxythymidine. The relative activities with the pyrimidine ribonucleosides and 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylthymine are not affected by the C-terminal deletions
additional information
-
expression of the enzyme in enzyme-deficient Escherichia coli strain KY895 confers resistnce against 3'-azido-2',3'-didehydro-3'-deoxythymidine at more than 0.1 mM
additional information
-
overexpression in cancer cell lines leads to increased cell sensitivity to several cytotoxic nucleoside analogues, expression of wild-type and mutant enzyme in an osteosarcoma cell line utilizing a replication-deficient retroviral vector reveals that the localization of the enzyme in cytosol or nucleus is not important for cell sensitivity and bystander cell killing
additional information
-
construction of libraries of hybrid enzymes by non-homologous recombination of the pyrimidinespecific human thymidine kinase 2 and the broad-specificity dNK from Drosophila melanogaster. Identification of chimeras that phosphorylate nucleoside analogs with higher activity than either parental enzyme, and that possess new activity towards the anti-HIV prodrug 2',3'-didehydro-3'-deoxythymidine
additional information
-
creation of mutants with increased specificity for several nucleoside analogs. The mutants have a reduced ability to phosphorylate pyrimidines, while the ability to phosphorylate purine analogs is relatively similar to the wild-type enzyme
additional information
-
engineering of multisubstrate nucleoside kinase targeted to the mitochondrial matrix and expression in thymidine kinase-1 deficient osteosarcoma cell line. Although the total deoxythymidine phosphorylation activity is similar in cells expressing multisubstrate nullceoside kinase in the nucleus or in the mitochondria, the cells expressing the enzyme in the mitochondria show higher sensitivity to the antiproliferative activity of pyrimidine nucleoside analogs, such as (E)-5-(2-bromovinyl)-2-deoxyuridine, 5-bromo-2-deoxyuridine, and 5-fluoro-2-deoxyuridine. Cells expressing the mitochondrial enzyme have an increased incorporation of [3H]dThd into DNA, due to a higher [3H]dTTP specific activity of the total dTTP pool in the cells in which the enzyme is targeted to the mitochondria
additional information
enzyme DmdNK is adsorbed on a solid ion exchange support (bearing primary amino groups) achieving an expressed activity of over 98%. Upon cross-linking with aldehyde dextran, the expressed activity is 30-40%, both biocatalysts (adsorbed or cross-linked) are stable at pH 10.0 and room temperature for 24 h with about 70% of retained activity. Optimization of the reaction conditions to 50 mM ammonium acetate, a substrate/ATP ratio of 1:1.25, 2 mM MgCl2, 37°C, pH 8.0, results in conversions of up to 90%
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Munch-Petersen, B.; Piskur, J.; Sondergaard, L.
The single deoxynucleoside kinase in Drosophila melanogaster, Dm-dNK, is multifunctional and differs from the mammalian deoxynucleoside kinases
Adv. Exp. Med. Biol.
431
465-469
1998
Drosophila melanogaster, Drosophila melanogaster S-2
brenda
Munch-Petersen, B.; Piskur, J.; Sondergaard, L.
Four deoxynucleoside kinase activities from Drosophila melanogaster are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase
J. Biol. Chem.
273
3926-3931
1998
Drosophila melanogaster, Drosophila melanogaster S-2
brenda
Johansson, M.; van Rompay, A.R.; Degreve, B.; Balzarini, J.; Karlsson, A.
Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster
J. Biol. Chem.
274
23814-23819
1999
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Munch-Petersen, B.; Knecht, W.; Lenz, C.; Sondergaard, L.; Piskur, J.
Functional expression of a multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster and its C-terminal deletion mutants
J. Biol. Chem.
275
6673-6679
2000
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Balzarini, J.; Degreve, B.; Hatse, S.; De Clercq, E.; Breuer, M.; Johansson, M.; Huybrechts, R.; Karlsson, A.
The multifunctional deoxynucleoside kinase of insect cells is a target for the development of new insecticides
Mol. Pharmacol.
57
811-819
2000
Drosophila melanogaster
brenda
Knecht, W.; Munch-Petersen, B.; Piskur, J.
Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster
J. Mol. Biol.
301
827-837
2000
Drosophila melanogaster
brenda
Zheng, X.; Johansson, M.; Karlsson, A.
Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol
Biochem. Biophys. Res. Commun.
289
229-233
2001
Drosophila melanogaster
brenda
Krawiec, K.; Kierdaszuk, B.; Shugar, D.
Inorganic tripolyphosphate (PPP(i)) as a phosphate donor for human deoxyribonucleoside kinases
Biochem. Biophys. Res. Commun.
301
192-197
2003
Drosophila melanogaster
brenda
Mikkelsen, N.E.; Johansson, K.; Karlsson, A.; Knecht, W.; Andersen, G.; Piskur, J.; Munch-Petersen, B.; Eklund, H.
Structural basis for feedback inhibition of the deoxyribonucleoside salvage pathway: studies of the Drosophila deoxyribonucleoside kinase
Biochemistry
42
5706-5712
2003
Drosophila melanogaster (Q9XZT6)
brenda
Eriksson, S.; Munch-Petersen, B.; Johansson, K.; Eklund, H.
Structure and function of cellular deoxyribonucleoside kinases
Cell. Mol. Life Sci.
59
1327-1346
2002
Bombyx mori, Drosophila melanogaster (Q9XZT6)
brenda
Knecht, W.; Sandrini, M.P.; Johansson, K.; Eklund, H.; Munch-Petersen, B.; Piskur, J.
A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines
Embo J.
21
1873-1880
2002
Drosophila melanogaster
brenda
Solaroli, N.; Bjerke, M.; Amiri, M.H.; Johansson, M.; Karlsson, A.
Active site mutants of Drosophila melanogaster multisubstrate deoxyribonucleoside kinase
Eur. J. Biochem.
270
2879-2884
2003
Drosophila melanogaster
brenda
Welin, M.; Skovgaard, T.; Knecht, W.; Zhu, C.; Berenstein, D.; Munch-Petersen, B.; Piskur, J.; Eklund, H.
Structural basis for the changed substrate specificity of Drosophila melanogaster deoxyribonucleoside kinase mutant N64D
FEBS J.
272
3733-3742
2005
Drosophila melanogaster
brenda
Piskur, J.; Sandrini, M.P.B.; Knecht, W.; Munch-Petersen, B.
Animal deoxyribonucleoside kinases: 'forward' and 'retrograde' evolution of their substrate specificity
FEBS Lett.
560
3-6
2004
Drosophila melanogaster (Q9XZT6)
brenda
Knecht, W.; Petersen, G.E.; Munch-Petersen, B.; Piskur, J.
Deoxyribonucleoside kinases belonging to the thymidine kinase 2 (TK2)-like group vary significantly in substrate specificity, kinetics and feed-back regulation
J. Mol. Biol.
315
529-540
2002
Drosophila melanogaster, Xenopus laevis (Q8UVZ9), Xenopus laevis, Bombyx mori (Q9BKL3), Bombyx mori
brenda
Johansson, K.; Ramaswamy, S.; Ljungcrantz, C.; Knecht, W.; Piskur, J.; Munch-Petersen, B.; Eriksson, S.; Eklund, H.
Structural basis for substrate specificities of cellular deoxyribonucleoside kinases
Nat. Struct. Biol.
8
616-620
2001
Drosophila melanogaster (Q9XZT6)
brenda
Knecht, W.; Petersen, G.E.; Sandrini, M.P.; Sondergaard, L.; Munch-Petersen, B.; Piskur, J.
Mosquito has a single multisubstrate deoxyribonucleoside kinase characterized by unique substrate specificity
Nucleic Acids Res.
31
1665-1672
2003
Anopheles gambiae (Q86LB8), Anopheles gambiae
brenda
Krawiec, K.; Kierdaszuk, B.; Kalinichenko, E.N.; Rubinova, E.B.; Mikhailopulo, I.A.; Eriksson, S.; Munch-Petersen, B.; Shugar, D.
Ability of adenosine-2'(3')-deoxy-3'(2')-triphosphates and related analogues to replace ATP as phosphate donor for all human and Drosphila melanogaster deoxyribonucleoside kinases
Nucleosides Nucleotides Nucleic Acids
22
1525-1529
2003
Drosophila melanogaster
brenda
Solaroli, N.; Bjerke, M.; Johansson, M.; Karlsson, A.
Investigation of the substrate recognition of Drosophila melanogaster nucleoside kinase by site directed mutagenesis
Nucleosides Nucleotides Nucleic Acids
23
1527-1529
2004
Drosophila melanogaster
brenda
Jordheim, L.P.; Galmarini, C.M.; Dumontet, C.
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells
Cancer Chemother. Pharmacol.
58
547-554
2006
Drosophila melanogaster
brenda
Legent, K.; Mas, M.; Dutriaux, A.; Bertrandy, S.; Flagiello, D.; Delanoue, R.; Piskur, J.; Silber, J.
In vivo analysis of Drosophila deoxyribonucleoside kinase function in cell cycle, cell survival and anti-cancer drugs resistance
Cell Cycle
5
740-749
2006
Drosophila melanogaster
brenda
Egeblad-Welin, L.; Sonntag, Y.; Eklund, H.; Munch-Petersen, B.
Functional studies of active-site mutants from Drosophila melanogaster deoxyribonucleoside kinase. Investigations of the putative catalytic glutamate-arginine pair and of residues responsible for substrate specificity
FEBS J.
274
1542-1551
2007
Drosophila melanogaster
brenda
Knecht, W.; Rozpedowska, E.; Le Breton, C.; Willer, M.; Gojkovic, Z.; Sandrini, M.P.; Joergensen, T.; Hasholt, L.; Munch-Petersen, B.; Piskur, J.
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs
Gene Ther.
14
1278-1286
2007
Drosophila melanogaster
brenda
Gerth, M.L.; Lutz, S.
Non-homologous recombination of deoxyribonucleoside kinases from human and Drosophila melanogaster yields human-like enzymes with novel activities
J. Mol. Biol.
370
742-751
2007
Drosophila melanogaster
brenda
Solaroli, N.; Zheng, X.; Johansson, M.; Balzarini, J.; Karlsson, A.
Mitochondrial expression of the Drosophila melanogaster multisubstrate deoxyribonucleoside kinase
Mol. Pharmacol.
72
1593-1598
2007
Drosophila melanogaster
brenda
Kamiya, H.; Ochiai, H.; Harashima, H.; Ito, M.; Matsuda, A.
Transient expression of Drosophila melanogaster deoxynucleoside kinase gene enhances cytotoxicity of nucleoside analogs
Nucleosides Nucleotides Nucleic Acids
25
553-560
2006
Drosophila melanogaster
brenda
Mikkelsen, N.E.; Munch-Petersen, B.; Eklund, H.
Structural studies of nucleoside analog and feedback inhibitor binding to Drosophila melanogaster multisubstrate deoxyribonucleoside kinase
FEBS J.
275
2151-2160
2008
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Clausen, A.R.; Girandon, L.; Knecht, W.; Survery, S.; Andreasson, E.; Munch-Petersen, B.; Piskur, J.
A multisubstrate deoxyribonucleoside kinase from plants
Nucleic Acids Symp. Ser.
52
489-490
2008
Arabidopsis thaliana
brenda
Knecht, W.; Mikkelsen, N.E.; Clausen, A.R.; Willer, M.; Eklund, H.; Gojkovic, Z.; Piskur, J.
Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine
Biochem. Biophys. Res. Commun.
382
430-433
2009
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Betham, B.; Shalhout, S.; Marquez, V.E.; Bhagwat, A.S.
Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli
DNA Repair
9
153-160
2010
Drosophila melanogaster
brenda
Ito, M.; Suda, Y.; Harashima, H.; Kamiya, H.
Cytotoxic effect of Drosophila deoxynucleoside kinase gene on replicating plasmid in HeLa cells
Biol. Pharm. Bull.
33
1223-1227
2010
Drosophila melanogaster
brenda
Serra, I.; Conti, S.; Piškur, J.; Clausen, A.; Munch-Petersen, B.; Terreni, M.; Ubiali, D.
Immobilized Drosophila melanogaster deoxyribonucleoside kinase (DmdNK) as a high performing biocatalyst for the synthesis of purine arabinonucleotides
Adv. Synth. Catal.
356
563-570
2014
Drosophila melanogaster (Q9XZT6)
-
brenda
Kamiya, H.; Ito, M.; Nishi, K.; Harashima, H.
In vivo selection of active deoxyribonucleoside kinase by a mutagenic nucleoside analog
J. Biotechnol.
228
52-57
2016
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Slot Christiansen, L.; Munch-Petersen, B.; Knecht, W.
Non-viral deoxyribonucleoside kinases - diversity and practical use
J. Genet. Genomics
42
235-248
2015
Anopheles gambiae (Q86LB8), Bombyx mori (Q9BKL3), Drosophila melanogaster (Q9XZT6)
brenda
Jiang, H.; Zhao, L.; Dong, X.; He, A.; Zheng, C.; Johansson, M.; Karlsson, A.; Zheng, X.
Tanshinone IIA enhances bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in nuclei and mitochondria
Oncol. Rep.
34
1487-1493
2015
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Fatima, M.; Ahmed, M.; Batool, F.; Riaz, A.; Ali, M.; Munch-Petersen, B.; Mutahir, Z.
Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells
Bosn. J. Basic Med. Sci.
19
342-349
2019
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda
Sun, Y.; Jiang, H.; Gu, M.; Zheng, X.
Efficacy of lentivirus-mediated Drosophila melanogaster deoxyribonucleoside kinase combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine or 1-beta-D-arabinofuranosylthymine therapy in human keloid fibroblasts
Mol. Med. Rep.
18
1660-1665
2018
Drosophila melanogaster (Q9XZT6)
brenda
Zhao, Y.; Jiang, H.; Gu, M.; Zu, C.; Zheng, X.
Gemcitabine resistance in triple-negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol
Oncol. Lett.
20
247
2020
Drosophila melanogaster
brenda
Liu, L.; You, J.; Zhu, Z.; Chen, K.; Hu, M.; Gu, H.; Liu, Z.; Wang, Z.; Wang, Y.; Liu, S.; Chen, L.; Liu, X.; Tian, Y.; Zhou, S.; Jiang, L.; Wan, J.
White stripe leaf8, encoding a deoxyribonucleoside kinase, is involved in chloroplast development in rice
Plant Cell Rep.
39
19-33
2020
Oryza sativa Indica Group
brenda
Chen, F.; Zhang, Y.; Daugherty, A.B.; Yang, Z.; Shaw, R.; Dong, M.; Lutz, S.; Benner, S.A.
Biological phosphorylation of an unnatural base pair (UBP) using a Drosophila melanogaster deoxynucleoside kinase (DmdNK) mutant
PLoS ONE
12
e0174163
2017
Drosophila melanogaster (Q9XZT6), Drosophila melanogaster
brenda